Adhesion- and stress-related adaptation of Glioma radiochemoresistance is circumvented by β1 integrin/JNK cotargeting

Oncotarget

Volumn 8, Issue 30, 2017, Pages 49224-49237

  Vehlow, Anne ^a,b,d   Klapproth, Erik ^a   Storch, Katja ^a,b   Dickreuter, Ellen ^a   Seifert, Michael ^c,d   Dietrich, Antje ^a,d   Bütof, Rebecca ^a,d   Temme, Achim ^a,d   Cordes, Nils ^a,b,d  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

GBM stem like cells; JNK; Orthotopic GBM mouse model; Radiochemoresistance; 1 integrin

Indexed keywords

ATM PROTEIN; BETA1 INTEGRIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 5; STRESS ACTIVATED PROTEIN KINASE; TEMOZOLOMIDE; HISTONE DEACETYLASE;

ADAPTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL INVASION; CHEMORADIOTHERAPY; CONTROLLED STUDY; DNA REPAIR; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; RADIOCHEMORESISTANCE; RADIOSENSITIZATION; SURVIVAL; THERAPY RESISTANCE; ANIMAL; BIOLOGICAL MODEL; BRAIN TUMOR; CELL CYCLE CHECKPOINT; CELL MOTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; GLIOMA; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGICAL STRESS; RADIATION RESPONSE; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR CELL LINE;

ADAPTATION, BIOLOGICAL; ANIMALS; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMORADIOTHERAPY; CHROMATIN ASSEMBLY AND DISASSEMBLY; DISEASE MODELS, ANIMAL; DNA REPAIR; GLIOMA; HISTONE DEACETYLASES; HUMANS; INTEGRIN BETA1; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MODELS, BIOLOGICAL; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85025841145     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.17480     Document Type: Article

References (56)

1. Stopschinski BE, Beier CP, Beier D. Glioblastoma cancer stem cells-from concept to clinical application. Cancer Lett. 2013; 338:32-40. doi: 10.1016/j.canlet.2012.05.033.
2. Mannino M, Chalmers AJ. Radioresistance of glioma stem cells: intrinsic characteristic or property of the "microenvironment-stem cell unit"? Mol Oncol. 2011; 5:374-86. doi: 10.1016/j.molonc.2011.05.001.
3. Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CLL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev. 2015; 29:1203-17. doi: 10.1101/gad.261982.115.
4. Vehlow A, Cordes N. Invasion as target for therapy of glioblastoma multiforme. Biochim Biophys Acta. 2013; 1836:236-44. doi: 10.1016/j.bbcan.2013.07.001.
5. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987-96. doi: 10.1056/NEJMoa043330.
6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10:459-66. doi: 10.1016/S1470-2045(09)70025-7.
7. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17:98-110. doi: 10.1016/j.ccr.2009.12.020.
8. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, et al. The Somatic Genomic Landscape of Glioblastoma. Cell. 2013; 155:462-77. doi: 10.1016/j.cell.2013.09.034.
9. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013; 45:1127-33. doi: 10.1038/ng.2762.
10. Weller M, Stupp R, Hegi M, Wick W. Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J. 18:40-4. doi: 10.1097/PPO.0b013e318243f6c9.
11. Bredel M, Zentner J. Brain-tumour drug resistance: the bare essentials. Lancet Oncol. 2002; 3:397-406. doi: 10.1016/S1470-2045(02)00786-6.
12. Eke I, Zscheppang K, Dickreuter E, Hickmann L, Mazzeo E, Unger K, Krause M, Cordes N. Simultaneous β1 integrin-EGFR Targeting and Radiosensitization of Human Head and Neck Cancer. J Natl Cancer Inst. 2015; 107. doi: 10.1093/jnci/dju419.
13. Eke I, Schneider L, Förster C, Zips D, Kunz-Schughart LA, Cordes N. EGFR/JIP-4/JNK2 signaling attenuates cetuximabmediated radiosensitization of squamous cell carcinoma cells. Cancer Res. 2013; 73:297-306. doi: 10.1158/0008-5472. CAN-12-2021.
14. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009; 9:537-49. doi: 10.1038/nrc2694.
15. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. Phosphorylation of c-jun mediated by MAP kinases. Nature. 1991; 353:670-4. doi: 10.1038/353670a0.
16. Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I, Tnani M, Holgado-Madruga M, Moscatello DK, Wong AJ. Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene. 2002; 21:5038-46. doi: 10.1038/sj.onc.1205593.
17. Tsuiki H, Tnani M, Okamoto I, Kenyon LC, Emlet DR, Holgado-Madruga M, Lanham IS, Joynes CJ, Vo KT, Wong AJ. Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Cancer Res. 2003; 63:250-5.
18. Li JY, Wang H, May S, Song X, Fueyo J, Fuller GN, Wang H. Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas. J Neurooncol. 2008; 88:11-7. doi: 10.1007/s11060-008-9529-1.
19. Yoon CH, Kim MJ, Kim RK, Lim EJ, Choi KS, An S, Hwang SG, Kang SG, Suh Y, Park MJ, Lee SJ. c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells. Oncogene. 2012; 31:4655-66. doi: 10.1038/onc.2011.634.
20. Kitanaka C, Sato A, Okada M. JNK Signaling in the Control of the Tumor-Initiating Capacity Associated with Cancer Stem Cells. Genes Cancer. 2013; 4:388-96. doi: 10.1177/1947601912474892.
21. Okada M, Sato A, Shibuya K, Watanabe E, Seino S, Suzuki S, Seino M, Narita Y, Shibui S, Kayama T, Kitanaka C. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. Int J Oncol. 2014; 44:591-9. doi: 10.3892/ijo.2013.2209.
22. Hynes RO. Integrins: Bidirectional, allosteric signaling machines. Cell. 2002; 110:673-87. doi: 10.1016/S0092-8674(02)00971-6.
23. Legate KR, Wickström SA, Fässler R. Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev. 2009; 23:397-418. doi: 10.1101/gad.1758709.
24. Cordes N, Hansmeier B, Beinke C, Meineke V, van Beuningen D. Irradiation differentially affects substratumdependent survival, adhesion, and invasion of glioblastoma cell lines. Br J Cancer. 2003; 89:2122-32. doi: 10.1038/sj.bjc.6601429.
25. Cordes N, Meineke V. Cell adhesion-mediated radioresistance (CAM-RR): Extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro. Strahlentherapie und Onkol. 2003; 179: 337-44. doi: 10.1007/s00066-003-1074-4.
26. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010; 10:9-22. doi: 10.1038/nrc2748.
27. Paolillo M, Serra M, Schinelli S. Integrins in glioblastoma: Still an attractive target? Pharmacol Res. 2016; 113:55-61. doi: 10.1016/j.phrs.2016.08.004.
28. Tabatabai G, Weller M, Nabors B, Picard M, Reardon D, Mikkelsen T, Ruegg C, Stupp R. Targeting integrins in malignant glioma. Target Oncol. 2010; 5:175-81. doi: 10.1007/s11523-010-0156-3.
29. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15:1100-8. doi: 10.1016/S1470-2045(14)70379-1.
30. Eke I, Storch K, Kästner I, Vehlow A, Faethe C, Mueller-Klieser W, Taucher-Scholz G, Temme A, Schackert G, Cordes N. Three-dimensional invasion of human glioblastoma cells remains unchanged by X-ray and carbon ion irradiation in vitro. Int J Radiat Oncol Biol Phys. 2012; 84:e515-23. doi: 10.1016/j.ijrobp.2012.06.012.
31. Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK. β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res. 2013; 73:3145-54. doi: 10.1158/0008-5472. CAN-13-0011.
32. Schittenhelm J, Tabatabai G, Sipos B. The role of integrins in primary and secondary brain tumors. Histol Histopathol. 2016; 31:1069-78. doi: 10.14670/HH-11-7741.
33. Sayeed A, Lu H, Liu Q, Deming D, Duffy A, McCue P, Dicker AP, Davis RJ, Gabrilovich D, Rodeck U, Altieri DC, Languino LR. β1 integrin-and JNK-dependent tumor growth upon hypofractionated radiation. Oncotarget. 2016; 7:52618-30. doi: 10.18632/oncotarget.10522.
34. Goel HL, Sayeed A, Breen M, Zarif MJ, Garlick DS, Leav I, Davis RJ, FitzGerald TJ, Morrione A, Hsieh CC, Liu Q, Dicker AP, Altieri DC, et al. β1 integrins mediate resistance to ionizing radiation in vivo by inhibiting c-Jun amino terminal kinase 1. J Cell Physiol. 2013; 228:1601-9. doi: 10.1002/jcp.24323.
35. Eke I, Deuse Y, Hehlgans S, Gurtner K, Krause M, Baumann M, Shevchenko A, Sandfort V, Cordes N. beta(1) Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest. 2012; 122:1529-40. doi: 10.1172/jci61350.
36. Motegi H, Kamoshima Y, Terasaka S, Kobayashi H, Houkin K. Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells. Neuropathology. 2014; 34:378-85. doi: 10.1111/neup.12117.
37. Falk M, Lukásová E, Kozubek S. Chromatin structure influences the sensitivity of DNA to gamma-radiation. Biochim Biophys Acta. 2008; 1783:2398-414. doi: 10.1016/j.bbamcr.2008.07.010.
38. Jakob B, Splinter J, Conrad S, Voss KO, Zink D, Durante M, Löbrich M, Taucher-Scholz G. DNA doublestrand breaks in heterochromatin elicit fast repair protein recruitment, histone H2AX phosphorylation and relocation to euchromatin. Nucleic Acids Res. 2011; 39:6489-99. doi: 10.1093/nar/gkr230.
39. Storch K, Eke I, Borgmann K, Krause M, Richter C, Becker K, Schröck E, Cordes N. Three-dimensional cell growth confers radioresistance by chromatin density modification. Cancer Res. 2010; 70:3925-34. doi: 10.1158/0008-5472.CAN-09-3848.
40. Geeleher P, Loboda A, Lenkala D, Wang F, LaCroix B, Karovic S, Wang J, Nebozhyn M, Chisamore M, Hardwick J, Maitland ML, Huang RS. Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. J Natl Cancer Inst. 2015; 107. doi: 10.1093/jnci/djv247.
41. Telles E, Seto E. Modulation of cell cycle regulators by HDACs. Front Biosci (Schol Ed). 2012; 4:831-9.
42. Dickreuter E, Eke I, Krause M, Borgmann K, van Vugt MA, Cordes N. Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells. Oncogene. 2015; 35:1353-62. doi: 10.1038/onc.2015.212.
43. Park CC, Zhang HJ, Yao ES, Park CJ, Bissell MJ. Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res. 2008; 68:4398-405. doi: 10.1158/0008-5472.CAN-07-6390.
44. Ritchie CK, Giordano A, Khalili K. Integrin involvement in glioblastoma multiforme: possible regulation by NF-kappaB. J Cell Physiol. 2000; 184:214-21. doi: 10.1002/1097-4652(200008)184:2 < 214::AID-JCP9>3.0.CO;2-Z.
45. Ahmed KM, Zhang H, Park CC. NF-B Regulates Radioresistance Mediated By 1-Integrin in Three-Dimensional Culture of Breast Cancer Cells. Cancer Res. 2013; 73:3737-48. doi: 10.1158/0008-5472.CAN-12-3537.
46. Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, et al. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell. 2013; 24:331-46. doi: 10.1016/j.ccr.2013.08.001.
47. Oberoi RK, Parrish KE, Sio TT, Mittapalli RK, Elmquist WF, Sarkaria JN. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro Oncol. 2016; 18:27-36. doi: 10.1093/neuonc/nov164.
48. Mailand N, Podtelejnikov A V, Groth A, Mann M, Bartek J, Lukas J. Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J. 2002; 21:5911-20.
49. Boutros R, Dozier C, Ducommun B. The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol. 2006; 18:185-91. doi: 10.1016/j.ceb.2006.02.003.
50. Huang C, Rajfur Z, Borchers C, Schaller MD, Jacobson K. JNK phosphorylates paxillin and regulates cell migration. Nature. 2003; 424:219-23. doi: 10.1038/nature01745.
51. Payne LS, Huang PH. The pathobiology of collagens in glioma. Mol Cancer Res. 2013; 11:1129-40. doi: 10.1158/1541-7786.MCR-13-0236.
52. Huijbers IJ, Iravani M, Popov S, Robertson D, Al-Sarraj S, Jones C, Isacke CM. A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion. PLoS One. 2010; 5:e9808. doi: 10.1371/journal. pone.0009808.
53. Günther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M, Lamszus K. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 2008; 27:2897-909. doi: 10.1038/sj.onc.1210949.
54. Cartellieri M, Koristka S, Arndt C, Feldmann A, Stamova S, von Bonin M, Töpfer K, Krüger T, Geib M, Michalk I, Temme A, Bornhäuser M, Lindemann D, et al. A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells. PLoS One. 2014; 9:e93745. doi: 10.1371/journal.pone.0093745.
55. Amer DA, Kretzschmar G, Müller N, Stanke N, Lindemann D, Vollmer G. Activation of transgenic estrogen receptorbeta by selected phytoestrogens in a stably transduced rat serotonergic cell line. J Steroid Biochem Mol Biol. 2010; 120:208-17. doi: 10.1016/j.jsbmb.2010.04.018.
56. Zscheppang K, Kurth I, Wachtel N, Dubrovska A, Kunz-Schughart LA, Cordes N. Efficacy of Beta1 Integrin and EGFR Targeting in Sphere-Forming Human Head and Neck Cancer Cells. J Cancer. 2016; 7:736-45. doi: 10.7150/jca.14232.